Iconovo announced that BNC Korea has acquired rights to manufacture and market generic versions of Ultibro indacaterol/glycopyrronium and Seebri glycopyrronium DPIs based on Iconovo formulations and the company’s ICOcap device. The deal covers a territory that includes Korea, Japan, China, Taiwan, Turkey, and Russia, as well as additional CIS and southeast Asian countries. According to Iconovo, BNC Korea will pay a €150,000 access fee, and the entire agreement is worth €550,000 plus royalties on any sales.
In Europe, the capsule-based ICOcap DPI is manufactured and sold by the Stevanato Group, and the inhaler was awarded the CE mark for clinical trial use in May 2020. Iconovo noted that the generic Ultibro and Seebri products are still available for licensing in Europe and in other territories.
Iconovo CEO Johan Wäborg commented, “Iconovo is looking forward to work with BNC Korea to bring these two products to market in a very important territory with over 2.7 billion inhabitants. BNC Korea is a regional dynamic company with fast decision-making and established distribution networks. With BNC Korea, we are confident that the products can be advanced to market in a fast and effective way. We will work closely with BNC Korea using our combined knowledge to form a strong alliance. This agreement is a validation of our technology and will make an important first block in our continuing licensing efforts for the remaining territory.”
Read the Iconovo press release.
